Rifampicin in non-tuberculous infections.
作者信息
Brumfitt W, Hamilton-Miller J M
出版信息
Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):496. doi: 10.1136/bmj.289.6443.496.
Abstract
摘要
相似文献
1
Rifampicin in non-tuberculous infections.利福平在非结核感染中的应用。
Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):496. doi: 10.1136/bmj.289.6443.496.
2
[Use of rifampicin in tuberculous patients with liver diseases].[利福平在肝病结核患者中的应用]
G Ital Chemioter. 1972 Jul;19(3):63-8.
3
[A double blind study of rifampicin].[利福平的双盲研究]
Hinyokika Kiyo. 1970 Oct;16(10):619-23.
4
5
[Clinical evaluation of rifampicin in urinary tract infections by double blind method].[利福平治疗尿路感染的双盲法临床评价]
Jpn J Antibiot. 1970 Aug;23(4):411-5.
6
Hepatic dysfunction in tuberculous patients treated with rifampicin and isoniazid.接受利福平与异烟肼治疗的结核病患者的肝功能障碍
Ir Med J. 1979 Oct 26;72(10):430-4.
7
Rifampicin: a clinical survey.利福平：一项临床调查。
Arzneimittelforschung. 1970 Oct;20(10):1546-51.
8
[Clinical application of rifampicin to common infections (author's transl)].
Jpn J Antibiot. 1974 Apr;27(2):69-72.
9
[The liver and rifampicin].[肝脏与利福平]
Cah Med. 1973 Jun 15;14(6):447-51.
10
[Interference of rifampicin on liver cytology].[利福平对肝脏细胞学的干扰]
Med Chir Dig. 1976 May 8;5(6):345-8.
引用本文的文献
1
Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.使用六种重新利用的药物阻断胶质母细胞瘤中的上皮-间质转化：EIS方案。
Oncotarget. 2017 Jun 1;8(37):60727-60749. doi: 10.18632/oncotarget.18337. eCollection 2017 Sep 22.
本文引用的文献
1
Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review).利福平与其他抗菌药物联用治疗非结核感染。650例患者的临床数据（综述）
Chemotherapy. 1981;27(5):368-402. doi: 10.1159/000238006.
2
Evidence that rifampicin can be used safely for non-tuberculous diseases.利福平可安全用于非结核疾病的证据。
Thorax. 1980 Oct;35(10):788-91. doi: 10.1136/thx.35.10.788.
3
Use of rifampin for the treatment of urinary tract infections.
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S573-82. doi: 10.1093/clinids/5.supplement_3.s573.
4
Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.
Int J Lepr Other Mycobact Dis. 1984 Mar;52(1):1-6.
5
Adverse effects of rifampin.
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S440-50. doi: 10.1093/clinids/5.supplement_3.s440.
6
Failure to stimulate antibodies in man after 7 days' high-dose treatment with rifampicin.利福平大剂量治疗7天后人体未能刺激产生抗体。
Lancet. 1981 Oct 17;2(8251):865. doi: 10.1016/s0140-6736(81)91123-5.
7
Rifampicin hepatitis. A clinical and histological study.利福平肝炎。一项临床与组织学研究。
Lancet. 1974 Mar 16;1(7855):421-5. doi: 10.1016/s0140-6736(74)92381-2.
8
Adverse reactions to rifampicin in antituberculosis regimens.
J Antimicrob Chemother. 1977 Mar;3(2):115-32. doi: 10.1093/jac/3.2.115.
9
Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosis.利福平的使用期限能否安全延长？结核分枝杆菌耐药菌株未出现的证据。
Lancet. 1977 Apr 2;1(8014):740-2. doi: 10.1016/s0140-6736(77)92179-1.
Zotero 插件